PLD3

Across TCGA pan-cancer cohorts, PLD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLD3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PLD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLD3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

COAD, HNSC, and LSCC are the cancer types where PLD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.873	1.000	.013	18	view →
HNSC	DFS	Median	All	0.975	0.909	.008	7	view →
LSCC	DFS	Tertile	III,IV	1.000	0.631	.017	7	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
CCRCC	OS	Median	II,III,IV	1.000	0.499	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLD3–COAD (DFS)

Open the COAD breakdown →